Chocolate sales rise among GLP-1 users, Lindt report finds

Chocolate sales are growing faster among people using weight-loss drugs than among the rest of the population, according to a new report.

Swiss chocolatier Lindt & Sprüngli cited data contradicting predictions that GLP-1 drugs would reduce interest in sweets.

Semaglutide drugs, like Ozempic and Wegovy, mimic the natural hormone GLP-1 (glucagon-like peptide-1), while tirzepatides (like Mounjaro and Zepbound) target both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors.

WEIGHT LOSS DRUGS COULD IMPACT SEXUAL HEALTH IN UNEXPECTED WAYS

Even as consumers taking these drugs reduce their intake of high-calorie foods like pasta and pizza, they still seek indulgence, Chief Executive Officer Adalbert Lechner said at a recent news conference.

Chocolate sales are growing faster among people using weight-loss drugs than among the rest of the population, according to a new report. (iStock)

“They’re moving toward higher-end products,” Lechner said. “Less is more – small rewards with a moment of happiness rather than mindless snacking.”

CLICK HERE TO SUBSCRIBE TO OUR HEALTH NEWSLETTER

An internal company study found that 15% of U.S. households use GLP-1 medications – and those households accounted for about 17.5% of chocolate sales in the data set. Lindt also reported that U.S. premium chocolate sales grew nearly 17% among GLP-1 users in 2025, compared to growth of about 6.5% among non-users.

OPRAH JOINS THE WAVE OF CELEBRITIES WHO REVEALED DRAMATIC WEIGHT LOSS IN 2025

“Consumers around the world continue to seek quality and moments of pleasure,” Lechner said in a press release.

Even though consumers taking GLP-1 drugs may be reducing their intake of high-calorie foods like pasta and pizza, they are still looking for indulgence, an industry official said. (iStock)

However, a 2025 study by Cornell University and Numerator suggests a different trend. This report found that GLP-1 users reduced their spending on high-calorie snacks by around 10%, with “equally significant decreases” for sweets, baked goods and cookies.

CLICK HERE FOR MORE HEALTH STORIES

“The main trend is a reduction in overall food purchases,” said Sylvia Hristakeva, assistant professor and co-author of the Cornell study. “Only a small number of categories are showing increases, and these are modest compared to the overall decline.”

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Despite these findings, Lechner said he does not view the popularization of weight-loss drugs as a threat to business.

One study found that GLP-1 users reduced their spending on high-calorie snacks by about 10%, with “equally significant decreases” for sweets, baked goods and cookies. (iStock)

Analysts expected that the introduction of GLP-1 pills would have a negative impact on the food industry over the next few years.

Experts predict that oral versions of weight-loss drugs will expand the market to include more men and younger patients.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Fox News Digital has reached out to pharmaceutical developers of GLP-1 drugs for comment.